Aromatase inhibitors: a useful additional therapeutic option for slowing down advanced bone age in boys with growth hormone deficiency.
Gözde Akın KağızmanlıDeniz Özalp KızılayÖzge BesciKübra Yüksek AcinikliSamim ÖzenKorcan DemirRuhsar Damla Gökşen ŞimşekEce BöberŞükran DarcanAyhan AbaciPublished in: Journal of endocrinological investigation (2023)
When used in addition to rhGH therapy in boys with GHD and advanced BA, AIs were observed to slow down the tempo of BA maturation after 1 year, compared to those who received rhGH treatment alone. AI therapy was found to be safe during the 1-year observation period and thus could be considered for preserving growth potential in these patients.
Keyphrases
- growth hormone
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- replacement therapy
- artificial intelligence
- stem cells
- patient reported outcomes
- bone mineral density
- risk assessment
- bone marrow
- mesenchymal stem cells
- climate change
- machine learning
- cell therapy
- patient reported
- deep learning
- postmenopausal women